Sorin denies acquisition bid for Fidia:
This article was originally published in Clinica
Sorin has rejected Italian press speculation linking it to a acquisition bid for the pharmaceutical company Fidia. The Italian biomedical company has stressed that it has no intention to diversify into the drugs industry. Il Mattino had linked the involvement in the bid of Snia's managing director - and Sorin's previous managing director - Umberto Rosa, to the possible exit of Sorin from Snia (see Clinica No 806, p 7). Snia is the Fiat chemical holding which owns Sorin. Dr Ezio Garibaldi, managing director of the Sorin group, emphasised that there are no plans for Sorin to leave Snia, although Snia may exit Fiat.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.